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Levels of carnitine and acylcarnitines in reconstituted red blood cell
samples washed with different concentrations of saline solutions
JOSÉ HENRY OSORIO, PhD1, MORTEZA POURFARZAM, PhD2
SUMMARY
Objective: To evaluate the percentage of carnitine and acylcarnitines remaining in red blood cells after washing them with
different concentrations of saline solution.
Materials and methods: Human blood samples were centrifuged and the blood cells were washed with different saline
solutions. The final pellet was resuspended in PBS for card preparation and tandem mass spectrometry analysis.
Results: It was found that carnitine, as well as short-chain, medium-chain, and long-chain acylcarnitines remain in red
blood cells at average percentages of 19.3; 34; 34; and 32%, respectively. Significant differences were found for carnitine
and acylcarnitine levels in blood washed with an isotonic solution compared to their levels using several hypotonic solutions
(p<0.05).
Conclusion: Because carnitine and acylcarnitines remained associated with the blood cells, we recommend using whole
blood to measure these metabolites.
Colomb Med. 2010; 41: 344-8
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Niveles de carnitina y acilcarnitinas en muestras de glóbulos rojos reconstituidos y lavados con solución salina a
diferentes concentraciones
RESUMEN
Objetivo: Evaluar el porcentaje de carnitina y acilcarnitinas que permanece en los glóbulos rojos, luego de lavarlos con
solución salina a diferentes concentraciones.
Materiales y métodos: Muestras de sangre humana fueron centrifugadas y los glóbulos rojos fueron lavados con solución
salina a diferentes concentraciones. El pellet obtenido, fue resuspendido en PBS para preparación de tarjetas y análisis por
espectrometría de masa en tandem.
Resultados: La carnitina, así como las acilcarnitinas de cadena corta, cadena media y cadena larga, permanecen en los
glóbulos rojos a porcentajes promedio de 19,3; 34; 34; and 32%, respectivamente. Se encontró diferencia significativa al
comparar los niveles de carnitina y acilcarnitinas de sangre lavada con una solución salina isotónica vs. varias hipotónicas
(p<0.05).
Conclusión: debido a que la carnitina y las acilcarnitinas permanecen en los glóbulos rojos, se recomienda el uso de sangre
entera para medir los niveles de estos metabolitos.
Colomb Med. 2010; 41: 344-8
Palabras clave: Carnitina; Acylcarnitinas, Acyl-CoA; Espectrometría de masa en tándem;
Glóbulos rojos; Metabolismo.
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Carnitine and acylcarnitine identification in body
fluids by using tandem mass spectrometry was developed
in the late 1980s1,2 and represents a valuable tool for the
diagnosis of some inherited metabolic defects, which
are difficult to diagnose by classical chromatographic
method. The method has the potential of effectively
screening for at least a dozen other disorders3-7. Some
authors suggest that a plasma carnitine and acylcarnitine
profile should be performed in all patients presenting
acute episode of hypoketotic hypoglycemia, Reye
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syndrome, hypertrophic cardiomyopathy, pericardial
effusion, cardiac failure, or rapid unexpected death
during the neonatal period or during infancy; also, heart
beat disorders during neonatal period, hypotonia with
unexplained failure to thrive, retinitis pigmentosa, or
even muscle pain triggered by exercise8. Measurement
of acylcarnitines by using tandem mass spectrometry
has been reported in whole blood9, plasma10, urine11,
amniotic fluid12, and bile13. There has been a permanent
question about the ideal fluid for carnitine and
acylcarnitine measurement. This study evaluates the
percentage of carnitine and acylcarnitines remaining in
red blood cells, after washing with different concen-
trations of saline solution to establish the recommended
fluid for carnitine and acylcrnitine analysis by tandem
mass spectrometry.
MATERIALS AND METHODS
The current study is experimental. All the chemicals
used were of analytical grade. Unlabelled acylcarnitine
and deuterated carnitine and acylcarnitines ([d3]C2cn,
[d9]C2cn, [d3]C3cn, [d3]C8cn, [d9]C8cn, [d3]C16cn,
[d3]C16cn) were obtained from Cambridge isotopes
laboratories (Andover, MA, USA). Butanolic HCL was
prepared by passing HCL gas through anhydrous n-
butanol (Sigma-aldrich Company, Ltd., Poole, UK) for
30 min. The concentration of the acid was determined
by back tritiation and adjusted.
Blood specimens and card preparation. Blood
samples used in this study were from ten adult healthy
volunteers who signed written consent. Blood was
collected into a tube containing EDTA (23.5 µmol/
tube). Aliquots of 20 ml were spotted on specimen
collection filter paper cards (N° 903, 1.88-mm thick;
Schleicher & Schuell, Dassel, Germany), dried overnight
at room temperature, vacuum sealed, and kept in the
freezer (-80oC) until analysis.
Extraction of blood acylcarnitines using microtiter
plates. Blood spots were punched from the card, (6.35-
mm diameter corresponding to 12 ml of whole blood, as
described (Hannon et al., 1997) and placed into
microtiter plates (96 samples for each plate). A total of
100 ml of the internal standard (containing the following
labeled acylcarnitines in 100 ml methanol: [d3]cn, 360
pmol; [d3]C2cn, 120 µmol; [d3]C3cn, 24 µmol; [d9]C8cn,
12 µmol; [d9]C16cn, 24 µmol) were added, plus 500 ml
of methanol to each sample. The plates were placed on
an orbital shaker (setting 750 rpm) for 30 min and then
sonicated for 15 min (sonic bath. 175SR). The plates
were returned to the shaker for an additional 2 h and
sonicated again for another 30 min. The filter discs
from the card punch were removed and the resulting
eluate was evaporated under air at 45°C until dry.
Derivatization process. An amount of 50 ml of 1 M
Butanolic HCl was added to each sample and incubated
at 60°C for 15 min. Samples were immediately returned
to the fume cupboard and evaporated under air at 45°C
until dry and re-dissolved in 100 ml of 70% (v/v)
acetonitrile in water prior to analysis by ESI -MS/MS.
Tandem mass spectrometry (MS/MS) analysis.
The blood analysis for acylcarnitines was performed by
using the following scan function: parents of m/z 85,
scan range 200-500 (m/z), collision energy 25 eV, cone
voltage 30 V, scan time 2.0 sec., interscan time 0.1 sec,
collision gas Argon, collision gas pressure 1.6-2 x
10-3 mBar. All analyses were performed by using a
Quattro II, triple quadrupole tandem mass spectrometer
(Micromass, Manchester, UK) equipped with an ion
spray source (ESI) and a micromass MassLynx data
system. The samples were introduced into the mass
spectrometer source by using a Jasco AS980 autosampler
and a Jasco PU980 HPLC pump. For these kinds of
works, the use of selected reaction monitoring for each
analyte could provide better quantification data;
however, analysis for acylcarnitines using parents of m/
z 85 is the routine method when analyzing samples from
patients, then we adopted this scan function.
Analysis of carnitine and acylcarnitine leves in red
blood cells. Blood samples (2 ml) collected with and
without anticoagulant were centrifuged (2300 g x 5
min) and the serum or plasma was retained for
acylcarnitine analysis. The pellet was resuspended to
the volume of 2 ml in each of the following saline
(NaCl) solutions: 0.9% (w/v) NaCl (i.e., 0.9 g/dl);
0.75% (w/v) NaCl (i.e., 0.75 g/dl); 0.65% (w/v) NaCl
(i.e., 0.65 g/dl); 0.55% (w/v) NaCl (i.e., 0.55 g/dl);
0.5% (w/v) NaCl (i.e., 0.5 g/dl); 0.45% (w/v) NaCl (i.e.,
0.45 g/dl); 0.4% (w/v) NaCl (i.e., 0.4 g/dl); 0.3% (w/v)
NaCl (i.e., 0.35 g/dl); 0.3% (w/v) NaCl (i.e., 0.33 g/dl);
0.3% (w/v) NaCl (i.e., 0.3 g/dl); 0% (w/v) NaCl (i.e., 0
g/dl). Samples were centrifuged (2,300 g x 5 min) and
the procedure was repeated twice. The final pellet was
resuspended in PBS for card preparation and tandem
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mass spectrometry analysis. All the samples were
extracted and free carnitine and acylcarnitines were
analysed. The procedure was performed five times for
each sample. Statistical comparisons were performed
by using one-way ANOVA (SigmaStat version 3.1
statistical software), followed by Dunnett’s test; p<0.05
was considered significant. According to article 11 on
its literal a. from resolution number 8430 promulgated
by the Ministry of Health for scientific, technical and
administrative guidelines for health research, the present
study is considered without risk. The study was approved
by the corresponding ethical committee.
RESULTS
The results obtained for the different saline solutions
are shown in Table 1. It was found that carnitine, as well
as short-chain, medium-chain and long-chain acylcar-
nitines remain in red blood cells at average percentages
of 19.3, 34, 34, and 32%, respectively, in a complete
hypotonic solution. It is evident that most acylcarnitines
are associated with blood cells and this may have
diagnostic implication as to whether whole blood or
plasma/serum is the preferred sample for acylcarnitine
analysis. It is clear that with decreasing saline concen-
tration the percentage of the remaining free carnitine
and acylcarnitines in the washed cell preparation
decreases, but this is probably due to the fact that at
lower saline concentrations (<0.4) some degree of
haemolysis occurs with the resulting leakage of carnitine
species in the matrix. Significant differences were
found for carnitine and acylcarnitine levels in blood
washed with an isotonic solution compared to its levels
using several hypotonic solutions (p<0.05).
DISCUSSION
It is unexpected to find carnitine and acylcarnitines
remaining in RBC because of the absence of
mitochondria and because they are energetically
independent of fatty-acid oxidation, with no demand
for classical carnitine-mediated fatty-acid transport.
However, there have been reports of the activity of
carnitine palmitoyltransferase as the essential enzyme
for the physiological expression of deacylation-
reacylation process, within the phospholipid fatty acid
membrane of human erythrocytes14,15. The results,
however, seem to have a far more important diagnostic
implication in that although free carnitine and short-
chain acylcarnitine are distributed equally between
Table 1
Concentration of carnitine and acylcarnitines in reconstituted red blood cell samples washed
with different concentrations of saline solution
% of analyte relative to whole blood
   Saline NaCl (g/dl)                        Free carnitine          C2cn         C8Cn       C16cn        C18cn
0.9 53.3 49.4 49 86.0 64
0.75 38.8 42.4 43.2 85.0 62
0.65 39.2 45.0 45.4 87.5 60
0.55 39.8 47.3 46.5 75.0 60
0.5 41.1 48.0 47.0 76.4 61
0.45 37.9 48.6 47.9 76.4 59.8
0.4 36.1 45.0 44.0 76.4 60
0.35 27.1 34.1 35.3 56.0 55.7
0.33 20.9 33.5 32.5 31.9 50.1
0.3 19.0 33.5 34.0 32.0 38
0 19.3 34.0 34.0 30.0 34.5
Abbreviations: C2cn , acetylcarnitine; C16cn , hexadecanoylcarnitine; C18cn, octadecanoylcarnitine; ud, undetectable.
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plasma and blood cells, long-chain acylcarnitines are
more associated with the latter. Serum carnitine
concentrations reflect less than 0.5% of the total body
carnitine pool of which 98% is represented by the
muscle mass, the remaining 1.5% being distributed
between the different organ systems and blood cells16.
The contribution of red blood cell to whole blood level
of carnitine increased significantly at delivery17.
However according to Mares-Perlman et al.18, carnitine
content found in red blood cells represents 73.6±4% of
whole-blood carnitine by human preterm neonates at
birth but declined to 42.2±14.1% by day 14. This
finding agrees with the percentage found in the present
study, and then it is possible to postulate that after this
day this percentage remains constant even to adulthood.
There is a close correlation between the plasma and
muscle carnitine levels, but carnitine in red blood cells
seems to represent a carnitine compartment of its own.
Carnitine level in red blood cells is probably less related
with fatty-acid metabolism of the mitochondrial than
with cell-membrane stabilization or buffer function for
Na-K-ATPase19. The role of the carnitine system is to
maintain homeostasis in the acyl-CoA pools of the cell,
keeping the acyl-CoA/CoA pool constant even under
conditions of very high turnover of the acyl-CoA20. The
enzyme carnitine palmitoyltransferase (CPT) properties
and locations are consistent with this21. Above all, the
carnitine derivatives can be moved across intracellular
barriers, so the carnitine system provides a shuttle
mechanism between microsomes, peroxisomes, and
mitochondria for complex lipid-synthetic and
breakdown pathways22. However, it was also demons-
trated that the acyl-carnitine pool could act as a source
of acyl groups, via the CoA pool, for the incorporation
into lipids when energy, required to activate free fatty
acids, is limited23.
CONCLUSION
Carnitine, along with short-chain, medium-chain
and long-chain acylcarnitines remain in red blood cells
at average percentages of 19.3, 34, 34, and 32%, respec-
tively, after washing with a total hypotonic solution.
Although some researchers recommend using serum or
plasma to measure these metabolites, we recommend
using whole blood.
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